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PURPOSE: To study the immunogenicity and the stability of the porcine pulmonary surfactant preparation produced by the
Instituto Butantan.
METHOD: Immunogenicity assay: Sixteen New-Zealand-White rabbits (1000 g body weight) were divided into 4 study groups.
Each group was assigned to receive either a) Butantan surfactant, b) Survanta® (Abbott Laboratories), c) Curosurf® (Farmalab
Chiesi), or d) no surfactant. The surfactants were administered intratracheally, and the animals were collected immediately before
and 60 and 180 days after surfactant administration. Sera were assayed for the presence of antisurfactant antibodies by enzyme-
linked immunosorbent assay (ELISA). Stability assay: The Butantan surfactant used in this assay had been stored for one year in
the refrigerator (4 to 8oC) and its stability was evaluated in distinct assay conditions using a premature rabbit model.
RESULTS: Immunogenicity assay: None of the surfactants analyzed triggered antibody immune responses against their components
in any of the animals. Stability assay: The results of this study demonstrate that Butantan surfactant was as effective as Curosurf
when both were submitted to the adverse circumstance of short- and long-term storage at room temperature. A similar level of
efficacy for the Butantan surfactant, as compared to Curosurf was demonstrated by the pulmonary dynamic compliance, ventilatory
pressure, and pressure-volume curve results.
CONCLUSION: The results of our study demonstrate that Butantan surfactant may be a suitable alternative for surfactant
replacement therapy.
KEYWORDS: Porcine pulmonary surfactant. Immunogenicity. Stability. Animal model.
INTRODUCTION
The Butantan Institute (Brazil) has produced a porcine
pulmonary surfactant preparation (Butantan surfactant) that
is obtained by organic extraction coupled with adsorption
on a cellulose derivative.1,2 The major advantage of this
preparation is the avoidance of large-volume, high-speed
centrifugation, thus making it feasible to produce in a low-
cost plant. This surfactant, as happens with all solvent-ex-
tracted mammalian surfactants, is composed mainly of
phospholipids with 2 hydrophobic polypeptides, SP-B and
SP-C, both of which are necessary for optimal surfactant
function for treatment of neonatal respiratory distress syn-
drome. This surfactant contains 76% phosphatidylcholine,
6% to 8% phosphatidyllethanolamine, 6% phosphati-
dylinositol + phosphatidylserine, and 4% to 6% sphingo-
myelin; 30% to 35% of the phosphatidylcholine is
dipalmitoyl phosphatidylcholine. The total content of pro-
tein is 5.6% of the total composition of the surfactant.
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The in vivo evaluation of Butantan surfactant compared
to other commercially available surfactants using the
preterm rabbit model showed similar pulmonary effects,
improving pulmonary functions as assessed by the decrease
of the ventilatory pressure and the increase of the dynamic
compliance.3
In order to demonstrate the efficacy and safety of this
surfactant in premature infants, it was first necessary to
study its immunogenicity in an adult rabbit model. The
need for studying immunogenicity is based on the possi-
bility that the introduction of the porcine surfactant pro-
teins into the airway of premature infants might provide
an antigenic stimulus with resultant immunological re-
sponse against those proteins.4–8 Furthermore, it was nec-
essary to evaluate the stability of this surfactant submitted
to adverse storage conditions9 in order to determine the ex-
piration date; this was done by testing efficacy in a pre-
mature rabbit model.
MATERIALS AND METHODS
The protocol was approved by the local ethics commit-
tee for animal experiments.
Immunogenicity assay
Sixteen New-Zealand-White rabbits (1000 g body
weight) were divided into groups of 4 animals. Each group
was assigned to receive either a) Butantan surfactant; b)
Survanta® Abbott Laboratories); c) Curosurf® (Farmalab
Chiesi); or d) no surfactant treatment. Each surfactant was
administered intratracheally (dose: 100 mg/kg), and the
animals were collected immediately before and 60 and 180
days after surfactant administration. Sera were assayed for
the presence of antisurfactant antibodies by enzyme-linked
immunosorbent assay (ELISA). Plates (96-wells, flat bot-
tom, Nunc Maxisorp Immunoplate) were coated overnight
at 4oC with Butantan surfactant, Survanta, and Curosurf
(1mg of protein/well) in 0.1 M carbonate-bicarbonate
buffer, pH 9.6, overnight at 4oC. Wells without antigen were
used to control assay specificity. Plates were washed with
PBS containing 0.05% Tween-20 (PBS-T) and incubated
overnight at 4oC with a blocking solution (10% fetal calf
serum) to reduce nonspecific binding. Plates were washed
again with PBS-T and incubated overnight at 4oC with se-
rial dilutions of the sera (nondiluted, 1:10 to 1:1,000), in
triplicate for each time point. Sera from the group receiv-
ing no surfactant treatment were used to control specificity.
After washing the plates, an appropriate dilution of don-
key antirabbit immunoglobulin horseradish-peroxidase con-
jugate (Sigma) was added. Plates were incubated for 2 h
at room temperature, washed again, and a substrate buffer
(0.2% O-phenylenediamine and 0.015% H2O2 in citrate-
phosphate buffer, pH 7.4) was added. The reaction was
stopped with 4.5 M H2SO4 and the absorbance measured
at 492 nm in a microplate reader. Results are reported as
the mean absorbance ± SD of triplicate wells. Absorbance
values above 0.1 were considered positive. Statistical analy-
sis of the data was performed by 1-way analysis of vari-
ance (ANOVA) and Tukey’s multiple comparison test, con-
sidering P < 0.05 as the significance level (GraphPad Prism,
2.0, 1995).
Stability assay
The Butantan surfactant used in this study was stored
for 1 year in the refrigerator (4oC to 8oC), and stability was
evaluated in distinct assay conditions as follows: The
Butantan surfactant used in this study were stored for 1 year
in the refrigerator (4oC to 8oC), and stability was evaluated
for Butantan and Curosurf in distinct assay conditions as
follows.
time point 0: immediately after removal from the refrig-
erator and warmed to 37oC for 5 minutes;
time point 1: 24 hours after removal from refrigerator and
kept at room temperature (24oC) before being warmed to
37oC for 5 minutes;
time point 2: 30 days after removal from refrigerator and
kept at 20o C-water bath temperature before being warmed
to 37o C for 5 minutes;
time point 3: 60 days after removal from refrigerator and
kept at 20o C-water bath temperature before warmed to 37o
C for 5 minutes;
time point 4: 90 days after removal from refrigerator and
kept at 20oC-water bath temperature before being warmed
to 37o C for 5 minutes;
time point 5: 180 days after removal from refrigerator and
kept at 20oC-water bath temperature before being warmed
to 37o C for 5 minutes;
Curosurf, used as the gold standard control, was within
its valid expiration date and was stored according to the
manufacture’s instructions.
Animal experiments
Birth and ventilation initiation
Pregnant rabbits at 27 days of gestation were sedated with
an intramuscular application of ketamine and acepromazine
solution (10 mg/kg and 0.1 mg/kg), followed by spinal
anesthesia with 2 mL of a solution 1:1 (vol:vol) of lidocaine
at 2% and bupivacaine at 0.5%. After laparotomy and hys-
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terotomy over a thermal mattress, the newborn rabbits were
removed, and the membranes and the placentas were taken.
The first premature rabbit removed from from the uterine
horn of each pregnant mother received no surfactant treat-
ment (prematurity control). The following premature rabbits
were removed from the uterus, one by one, and alternately
from the right or left side. After being dried and the weighed,
each animal was anesthetized with intraperitoneal ketamine-
acepromazine (10 mg/kg – 0.1 mg/kg) and submitted to tra-
cheostomy with a metal cannula (internal diameter of 1 mm).
In strict accordance with this protocol, 94 New Zealand
White premature rabbits were delivered and randomized into
2 groups according to the surfactant treatment: Butantan sur-
factant (n = 47) and Curosurf (n = 47). For each of the study
time points, 7 to 8 animals were used for Butantan surfactant,
7 to 8 for Curosurf. The surfactant dose used in both groups
and at all time points described above was 100 mg/kg/body
weight.Before the initiation of ventilation, endotracheal ad-
ministration of surfactant was performed, followed by
manual ventilation with a self-inflating bag for about 10 sec-
onds. Afterwards, the animals received pancuronium (20 µg)
through the intraperitoneal route so that there would be no
spontaneous respiration.
Mechanical Ventilation
Mechanical respiration was started (INTER 3â-
Intermed-São Paulo) using the respiratory rate (RR) of 60
cycles/min, and inspired oxygen concentration (FiO2) of
21%; peak inspiratory pressure (PIP) was adjusted to to ac-
quire a tidal-volume of 8 ml/kg,10 and a positive end-ex-
piratory (PEEP) of 0 cm H2O; inspiratory and expiratory
times were 0.5 seconds; this controlled assisted ventilation
protocol was maintained over a 15-minute period.
After the initiation of the ventilation, tidal-volume (Vt)
data, dynamic compliance (DC), and ventilatory pressure
(VP) at 5, 10, and 15 minutes were determined. Respira-
tory mechanics data were recorded through a pressure sen-
sor (Validyne®, model DP45 - 24) connected to a software
specifically developed for respiratory mechanical analysis
(LabVIEW 5.1®, National Instruments, Austin, USA and
R. A. Eletro Sistemas LTDA, Campinas, Brazil). The tidal-
volume was evaluated through the integration of the flow
and time signals obtained from a pneumotacograph (Model
8431 series - Hans Rudolph® Inc., Kansas City, USA) also
connected to a pressure sensor (Validyne®, model DP45 -
14), and using the same software for data acquisition.
Ventilatory pressure was considered to be the difference
between the PIP and the PEEP, and the dynamic compli-
ance (mL/cm H2O·kg) was calculated by dividing Vt (mL/
kg) by VP (cm H2O). The PIP adjustment was performed
as necessary in order to maintain the target Vt of 8 ml/kg
for 30 seconds before every measurement.
Pressure-Volume Curve
After 15 minutes of ventilation, the animals received
deep sedation with intraperitoneal sodium pentobarbital (25
mg/kg), followed by tracheal clamping for 5 minutes. Ani-
mals were immediately sacrificed with an intrathecal in-
jection of 0.5 mL of lidocaine at 2%, and the P-V curve
was obtained by measuring the lung volume 30 seconds af-
ter insufflation, using increments of 5 cm H2O until a maxi-
mum pressure of 30 cm H2O was attained; this was fol-
lowed by the deflation of the lung by decrements of 5 cm
H2O to 0 cm H2O.
Statistical analysis
The statistical analysis of the stability assay data was
performed by Student t test for parametric data, and by
Mann-Whitney test for nonparametric data considering P
< 0.05 to be the level of statistical significance.
RESULTS
Immunogenicity assay
The presence of antibodies against Butantan surfactant,
Survanta, and Curosurf was evaluated in the sera of the ani-
mals at several dilutions and time points. Antibody response
profiles were similar in all groups and time points. There-
fore, we only present the results obtained at the 1:100 di-
lution (Figure 1). There were no significant statistical dif-
ferences in antibody titers among the studied groups. None
of the surfactants analyzed triggered antibody immune re-
sponses against their components in these animals.
Stability assay
Ninety-four New Zealand White premature rabbits were
delivered; the recorded weights of the animals assigned to
the Butantan surfactant and to the Curosurf groups were
29.9 ± 2.6 g and 29.9 ± 2.9 g (mean ± SD), respectively.
Respiratory mechanics ie, tidal volume (VT), dynamic
compliance, ventilatory pressure, and pressure-volume
curve are shown in Figures 2, 3, 4, 5, 6, and 7. It can be
seen that the Butantan surfactant and Curosurf maintained
similar effectiveness throughout the adverse storage con-
ditions. Similar efficacy was demonstrated by the dynamic
compliance, ventilatory pressure, and pressure-volume
curve results.
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DISCUSSION
Antibody levels detected after surfactant administration
were not statistically different from levels detected before
administration. It has been demonstrated that in neonatal
respiratory distress syndrome, there is an increase in the
pulmonary capillary permeability, causing a release of sur-
factant proteins into the circulation that could induce an
immune response.11 Based on our results, we speculate that
during lung development, surfactant proteins could also be
released into the circulation eliciting a transitory immune
response. This could explain the basal levels observed in
our experiments in all groups.
According to the Brazilian Federal Health Agency,
ANVISA,9 and in agreement with international guidelines,
all new drugs must be analyzed concerning stability before
usage in a clinical setting.
Stability tests describe drug behavior when submitted
to adverse environmental conditions. Among environmen-
tal factors, such as temperature, moisture, and light, we
studied how the Butantan surfactant responded to differ-
Figure 1 - Antibody levels against (a) Butantan, (b) Survanta, and (c)
Curosurf surfactant proteins in the sera of rabbits after intratracheal
administration. Bars represent mean absorbance ± SD obtained for a 1:100
dilution of the sera. Data were analyzed by one-way analysis of variance
(ANOVA) and Tukey’s multiple comparison test considering P<0.05
(GraphPad Prism, 2.0, 1995).
Figure 3 - Time point 1 (24 hours after removal from refrigerator and kept
at room temperature (24o C) before being warmed to 37oC for 5 minutes):
data for tidal-volume (Vt), dynamic compliance (DC), ventilatory pressure
(VP), and pressure-volume curve (mean ± SD) were analyzed by the Student
t test (parametric data) or Mann-Whitney test (non-parametric data).
Figure 2 - Time point 0 (immediately after removal from the refrigerator
and being warmed to 37oC for 5 minutes) data for tidal-volume (Vt), dynamic
compliance (DC), ventilatory pressure (VP), and pressure-volume curve
(mean ± SD). Data were analyzed by the Student t test (parametric data) or
Mann-Whitney test (nonparametric data).
157
CLINICS 2006;61(2):153-60 Analysis of the immunogenicity and stability of a porcine pulmonary surfactant preparation
Precioso AR et al.
Figure 4 - Time point 2 (30 days after being kept at 20oC-water bath
temperature before being warmed to 37oC for 5 minutes) data for tidal-
volume (Vt), dynamic compliance (DC), ventilatory pressure (VP), and
pressure-volume curve (mean ± SD). Data were analyzed by the Student t
test (parametric data) or Mann-Whitney test (nonparametric data).
Figure 5 - Time point 3 (60 days after being kept at 20o C-water bath
temperature before being warmed to 37oC for 5 minutes) data for tidal-
volume (Vt), dynamic compliance (DC), ventilatory pressure (VP), and
pressure-volume curve (mean ± SD). Data were analyzed by the Student t
test (parametric data) or Mann-Whitney test (nonparametric data).
Figure 7 - Time point 5 (180 days after being kept at 20o C-water bath
temperature before being warmed to 37oC for 5 minutes) data for tidal-
volume (Vt), dynamic compliance (DC), ventilatory pressure (VP), and
pressure-volume curve (mean ± SD). Data were analyzed by the Student t
test (parametric data) or Mann-Whitney test (nonparametric data).
Figure 6 - Time point 4 (90 days after being kept at 20o C-water bath
temperature before being warmed to 37o C for 5 minutes) data for tidal-
volume (Vt), dynamic compliance (DC), ventilatory pressure (VP), and
pressure-volume curve (mean ± SD). Data were analyzed by the Student t
test (parametric data) or Mann-Whitney test (nonparametric data).
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ent storage temperatures over time. We performed the stud-
ies with a premature rabbit model developed in our labo-
ratory, which has been shown to be ideal for testing the
efficacy of exogenous surfactant for treating premature rab-
bits with respiratory distress syndrome (SDR). Our results
demonstrated that the Butantan surfactant was as effective
as Curosurf even when submitted to adverse storage con-
ditions over time. This can be seen in all time points stud-
ied, including time point 5, for which the surfactants were
kept in a water bath at 20ºC for 180 daysThe similar effi-
cacy between Butantan surfactant and Curosurf was dem-
onstrated by the dynamic compliance, ventilatory pressure,
and pressure-volume curve results.
In conclusion, the results of our study are relevant not
only from the clinical point of view concerning the effi-
cacy and safety of Butantan surfactant, but also for eco-
nomical reasons, since Butantan surfactant may be a suit-
able as an alternative replacement therapy.
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RESUMO
Precioso AR, Sakae PPO, Mascaretti RS, Kubrusly FS,
Gebara VCBC, Iourtov D et al. Análise da imunogenicidade
e da estabilidade do surfactante pulmonar de origem
porcina administrado em coelhos. Clinics. 2006;61(2):153-
60.
OBJETIVO: Estudar a imunogenicidade e a estabilidade
do surfactante de origem porcina produzido pelo Instituto
Butantan.
Método: Experimento imunogenicidade: 16 coelhos da raça
New-Zealand-White (Peso de 1000g) foram divididos em
grupos de 4 animais. Cada grupo foi designado para rece-
ber: a) Surfactante do Butantan, b) Survanta® (Abbott
Laboratories), c) Curosurf (Farmalab Chiesi) e d) nenhum
tratamento com surfactante. Os surfactantes foram admi-
nistrados via intratraqueal e o sangue dos animais foi co-
letado antes, 60 e 180 dias após a administração do
surfactante. O soro obtido foi analisado quanto a presença
de anticorpos anti-surfactante pelo método ELISA
(enzyme-linked immunosorbent assay). Experimento esta-
bilidade: O surfactante do Butantan usado neste experimen-
to tinha sido armazenado por um ano em refrigerador (4 a
8°C) e sua estabilidade foi analisada em condições distin-
tas de experimentação, usando o modelo de coelho prema-
turo.
RESULTADOS: Experimento imunogenicidade: Nenhum
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